Project Grant R03CA297201
Award Date
12/1/24
Completion Date
11/30/26
Dollars Obligated
$157K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
New Jersey, USA
Similar Awards
This $510,306 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to advance the understanding of virus-host interactions for developing a cure against chronic hepatitis B virus (HBV) infections. The primary goal is to investigate the mechanisms by which interferon-alpha treatment can lead to a functional cure for HBV, as well as explore the impact of HBV...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $634,061 to the University of Maryland, Baltimore to study the role of tumor-associated plasmacytoid dendritic cells (TAPDC) in the tumor immune microenvironment (TIME) of liver cancer or hepatocellular carcinoma (HCC) during HIV infection. The 5-year project aims to: 1) Characterize how TAPDC reprogram the HCC TIME in HCC-HIV mouse models and human samples; 2) Define how TAPDC modulate...
This federal Project Grant award of $397,772.00 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support the development of novel computational methods for profiling the cancer virome and analyzing microbial strain genetics in cancer-associated microbiomes. The primary objectives are to: 1) create computational tools to accurately identify and quantify viruses in shotgun metagenomes and metatranscriptomes, and 2) develop biostatistical methods to...
This Project Grant award, titled "EXPLOITING THERAPEUTIC VULNERABILITIES IN HEPATOCELLULAR CARCINOMA (ELEVATE)", is funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research). The $2,678,459 award aims to advance the understanding of molecular mechanisms regulating non-alcoholic steatohepatitis (NASH)-associated hepatocellular carcinoma (HCC) and develop novel combinatorial treatment approaches. The award supports four research projects, an administrative core, a...
This $435,506 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to understand how the Epstein-Barr virus (EBV) contributes to the development and progression of various types of non-Hodgkin's lymphoma, including those associated with HIV infection. The University of North Carolina at Chapel Hill will conduct this research over a 5-year period from September 2024 to August 2029. The key objectives are to: 1) identify how EBV...
The National Cancer Institute (NCI) awarded a $936,746 Project Grant (CFDA 93.396 - Cancer Biology Research) to Rutgers, The State University of New Jersey on December 1, 2024. The grant will fund research to further characterize the biology of the BTLP3A gene and its impact on the orchestration of protective immunity in ovarian cancer. The research aims to understand how cancer cell-intrinsic mitochondrial stress responses influence protective immunity, as emerging evidence indicates that...
This $104,096 federal Project Grant award, provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), supports research to identify genetic dependencies specific to subtypes of hepatocellular carcinoma (HCC). The project will utilize a hybrid in vivo and in silico approach to determine whether HCC genetic dependencies demonstrate subtype specificity based on pathomolecular features. Specific aims include: 1) using in vivo loss-of-function screening to assess...
This $127,952 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) will support research at George Washington University to study the role of the enzyme HDAC11 in liver cancer progression. The research has two main aims: 1) to determine if HDAC11-mediated modifications to the splicing factor SF3B2 impact alternative mRNA splicing in liver cancer cells, and 2) to evaluate the potential of HDAC11-specific inhibitors as a new liver cancer treatment...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Tulane University is focused on investigating the role of the long non-coding RNA CRNDE in hepatocellular carcinoma (HCC) and its impact on tumor-infiltrating lymphocytes (TILs). The total award amount is $468,139, with a project period from March 15, 2025 to February 28, 2030. The key objectives of this research project are to elucidate the molecular mechanisms by which HCC-derived CRNDE...
This federal Project Grant award of $147,486, awarded on December 1, 2025 by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), supports research by Baylor College of Medicine to develop a novel "RECON" immune tolerization strategy. The goal is to investigate the trade-offs between oncogene pathogenicity and immunogenicity, which could enable dissection of the genetic and phenotypic alterations governing immune evasion independently of tumorigenesis during...